ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1? STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS

Kartik Raghupathi  ¹     Robin Osterhout  ¹     Brian G. Feagan  ²     William Sandborn  ³     Courtney Van Biene  ³     Allan Olson  ³     Richard Aranda  ³     Barrett G. Levesque  ³     Silvio Danese  ^4    
1 Gossamer Bio, Inc., San Diego, United States
² Alimentiv, Inc., London, Canada
³ University of California San Diego, San Diego, United States
⁴ Humanitas Research and Teaching Hospital, Milan, Italy

Topic
IBD, Immunology

Session
IBD: Clinical trials III

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)